Table 1.

Study instruments and time points

Instrument/measure	Screening	Baseline (4 weeks window from consent)	12 weeks postbaseline (±2 weeks window)	24 weeks postbaseline (±2 weeks window)*
Electronic health record review	X
Adapted NCCN Distress Thermometer	X
Medication Event Monitoring System (MEMS Caps)		To be used throughout the 24-week study period
Demographics		X
Medication Adherence Report Scale-5		X	X	X
Breast Cancer Prevention Trial Symptom Checklist		X	X	X
Cancer Therapy Satisfaction Questionnaire		X	X	X
Hospital Anxiety and Depression Scale		X	X	X
Functional Assessment of Cancer Therapy		X	X	X
Measure of Current Status		X	X	X
Beliefs About Medications Questionnaire –Adjuvant Endocrine Therapy (AET)		X	X	X
Multidimensional Scale of Perceived Social Support		X	X	X
Self-Efficacy in Appropriate Medication Use Scale		X	X	X
Self-Efficacy For Managing Symptoms and Taking AET Questionnaire (Self-Efficacy For Symptoms)		X	X	X
Patient-Reported Outcomes Measurement Information System – Cognitive Function – Short Form 4a		X	X	X
Client Satisfaction Questionnaire (CSQ)*			X
Supplemental Medication Diary	To serve as optional as-needed supplement to MEMS Caps (eg, on vacation)

*CSQ will be administered to intervention participants only.

NCCN, National Comprehensive Cancer Network.